http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Dec 2025 16:33:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clearside+Biomedical%2C+++++For%3A+Dec+08/25712795.html si-local-file:///var/storage/secattach/20251208/25712795.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clearside+Biomedical%2C+++++For%3A+Dec+08/25712795.html Mon, 08 Dec 2025 16:33:00 -0500 CLSD CLSDQ O.13676072 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clearside+Biomedical%2C+++++For%3A+Dec+08/25712795.html si-local-file:///var/storage/secattach/20251208/25712795.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clearside+Biomedical%2C+++++For%3A+Dec+08/25712795.html Mon, 08 Dec 2025 16:33:00 -0500 CLSD CLSDQ O.13676072 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clearside+Biomedical%2C+++++For%3A+Dec+08/25712795.html si-local-file:///var/storage/secattach/20251208/25712795.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clearside+Biomedical%2C+++++For%3A+Dec+08/25712795.html Mon, 08 Dec 2025 16:33:00 -0500 CLSD CLSDQ O.13676072 http://www.streetinsider.com/SEC+Filings/Form++25+++++++++Clearside+Biomedical%2C++++++++++++++++/25712545.html si-local-file:///var/storage/secattach/20251208/25712545.html http://www.streetinsider.com/SEC+Filings/Form++25+++++++++Clearside+Biomedical%2C++++++++++++++++/25712545.html Mon, 08 Dec 2025 16:19:00 -0500 CLSD CLSDQ O.13676072 http://www.streetinsider.com/SEC+Filings/Form++25+++++++++Clearside+Biomedical%2C++++++++++++++++/25712545.html si-local-file:///var/storage/secattach/20251208/25712545.html http://www.streetinsider.com/SEC+Filings/Form++25+++++++++Clearside+Biomedical%2C++++++++++++++++/25712545.html Mon, 08 Dec 2025 16:19:00 -0500 CLSD CLSDQ O.13676072 http://www.streetinsider.com/SEC+Filings/Form++25+++++++++Clearside+Biomedical%2C++++++++++++++++/25712545.html si-local-file:///var/storage/secattach/20251208/25712545.html http://www.streetinsider.com/SEC+Filings/Form++25+++++++++Clearside+Biomedical%2C++++++++++++++++/25712545.html Mon, 08 Dec 2025 16:19:00 -0500 CLSD CLSDQ O.13676072 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clearside+Biomedical%2C+++++For%3A+Nov+23/25663184.html si-local-file:///var/storage/secattach/20251125/25663184.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clearside+Biomedical%2C+++++For%3A+Nov+23/25663184.html Tue, 25 Nov 2025 16:06:00 -0500 CLSD O.13676072 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clearside+Biomedical%2C+++++For%3A+Nov+23/25663184.html si-local-file:///var/storage/secattach/20251125/25663184.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clearside+Biomedical%2C+++++For%3A+Nov+23/25663184.html Tue, 25 Nov 2025 16:06:00 -0500 CLSD O.13676072 http://www.streetinsider.com/Corporate+News/Clearside+Biomedical+files+for+Chapter+11+bankruptcy%2C+seeks+asset+sale/25652133.html <p>Clearside Biomedical Inc. (NASDAQ: CLSD) filed a voluntary Chapter 11 bankruptcy petition in the U.S. Bankruptcy Court for the District of Delaware and plans to pursue an asset sale process.</p><p>The biopharmaceutical company intends to file a motion seeking court authorization for an auction under Section 363 of the U.S. Bankruptcy Code. The proposed bidding procedures would require interested parties to submit binding offers to acquire Clearside's assets in whole or in part, purchased free and clear of liens and interests.</p><p>"Our Board of Directors and management team have thoroughly assessed all of our strategic options and believe that this Chapter 11 http://www.streetinsider.com/Corporate+News/Clearside+Biomedical+files+for+Chapter+11+bankruptcy%2C+seeks+asset+sale/25652133.html Mon, 24 Nov 2025 07:05:30 -0500 CLSD http://www.streetinsider.com/Hot+Corp.+News/Clearside+Biomedical+files+for+Chapter+11+bankruptcy%2C+seeks+asset+sale/25652133.html <p>Clearside Biomedical Inc. (NASDAQ: CLSD) filed a voluntary Chapter 11 bankruptcy petition in the U.S. Bankruptcy Court for the District of Delaware and plans to pursue an asset sale process.</p><p>The biopharmaceutical company intends to file a motion seeking court authorization for an auction under Section 363 of the U.S. Bankruptcy Code. The proposed bidding procedures would require interested parties to submit binding offers to acquire Clearside's assets in whole or in part, purchased free and clear of liens and interests.</p><p>"Our Board of Directors and management team have thoroughly assessed all of our strategic options and believe that this Chapter 11 http://www.streetinsider.com/Hot+Corp.+News/Clearside+Biomedical+files+for+Chapter+11+bankruptcy%2C+seeks+asset+sale/25652133.html Mon, 24 Nov 2025 07:05:30 -0500 CLSD http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344 http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344 http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344 http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344 http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344 http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344 http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344 http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344 http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344 http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Press+Releases/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344 http://www.streetinsider.com/Globe+Newswire/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Globe+Newswire/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344 http://www.streetinsider.com/Globe+Newswire/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Globe+Newswire/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344 http://www.streetinsider.com/Globe+Newswire/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Globe+Newswire/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344 http://www.streetinsider.com/Globe+Newswire/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Globe+Newswire/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344 http://www.streetinsider.com/Globe+Newswire/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html <p align="center"><em>- Intended to Maximize Stakeholder Value Through Structured Process -</em></p> <p align="center"><em>- Validated SCS Microinjector</em><em>®</em><em> Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -</em><br/><br/> <em>- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy -</em></p> <p align="center"><em>- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -<br/><br/></em></p> <p align="justify">ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a http://www.streetinsider.com/Globe+Newswire/Clearside+Biomedical+to+Pursue+Strategic+Sale+of+its+Business+Through+Voluntary+Chapter+11+Process/25652130.html Mon, 24 Nov 2025 07:05:00 -0500 A.06822034 A.07414818 A.13032755 A.27152739 CLSD O.00383696 O.03227691 O.09666320 O.13676072 O.20026344